Canterbury anti-neutropil cytoplasmic antibody (ANCA) associated vasculitis observational study
Not Applicable
Withdrawn
- Conditions
- Anti-neutropil cytoplasmic antibody (ANCA) associated vasculitidies including Wegeners granulomatosis (WG)Inflammatory and Immune System - Autoimmune diseases
- Registration Number
- ACTRN12608000012370
- Lead Sponsor
- isa Stamp
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
ANCA associated vasculitis defined by American College of Rheumatology (ACR), Chapel Hill Consensus Criteria or Watts 2007 algorithm
Exclusion Criteria
Unable to provide informed consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This is an observational study of disease outcomes. Participants will be assessed using a variety of meausres including the SF36, Bath vasculitis activity score for wegeners granulomatosis (BVASWG), vasculitis damage index (VDI) and the disease extent index (DEI).[Patients will be followed indefinitely to determine long term outcomes. Patients will be seen at least 3-6 monthly];Response to and complications from therapy. Clinical and laboratory measures will be used to determine complications including bone marrow suppression and infectio rates[Patients will be followed indefinitely to determine long term outcomes. Patients will be seen at least 3-6 monthly]
- Secondary Outcome Measures
Name Time Method Disease relapse[Patients will be followed indefinitely to determine long term outcomes. Patients will be seen at least 3-6monthly]